News

News Archive

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Awareness Day

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Awareness Day

We at Menarini are committed in making a difference in lives of patients. 23rd January 2021 marks the second annual BPDCN Awareness Day (#BPDCNday)

Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)...

Select a Year from the Archive

Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Follow our blog

Discover our stories from all over the world

Read More